1-20 of 50
Antonio Giordano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study

Antonio Giordano, Nisha Unni, Senthil Damodaran, Hope Rugo, Timothy Crook, Thomas Bachelot, Federico Piacentini, Hector Soto Parra, Ian Krop, Masashi Shimura, Gareth Tomlinson, Maciej Gil, Nicholas Turner, Fabrice André
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-06-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-06-07
Published: 02 May 2024
View article titled, Abstract PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study
Journal Articles

Abstract PO3-01-09: Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+/HER2- breast cancer

Chiara Corti, Xiangying Chu, Pedro Exman, Danielle Kline, Nolan Priedigkeit, Nabihah Tayob, Erica Mayer, Adrienne Waks, Melissa Hughes, Antonio Giordano, Giuseppe Curigliano, Nancy Lin, Tari King, Rinath Jeselsohn, Deborah Dillon, Elizabeth Mittendorf, Sara Tolaney
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-01-09.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-01-09
Published: 02 May 2024
View article titled, Abstract PO3-01-09: Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+/HER2- breast cancer
Journal Articles

Abstract PO3-20-06: TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer

Paolo Tarantino, Samuel Niman, Antonio Giordano, Faina Nakhlis, Jennifer Bellon, Wendy Woodward, Azadeh Nasrazadani, Sadia Saleem, Anthony Lucci, Michelle DeMeo, Naoto Ueno, Sara Tolaney, Vicente Valero, Meredith Regan, Rachel Layman, Filipa Lynce
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-20-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-20-06
Published: 02 May 2024
View article titled, Abstract PO3-20-06: TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer
Journal Articles

Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

Sara Hurvitz, Fabrice André, Massimo Cristofanilli, Giuseppe Curigliano, Antonio Giordano, Hyo Han, Miguel Martín, Barbara Pistilli, Hope Rugo, Robert Wesolowski, Igor Gorbatchevsky, Sibylle Loibl
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-20-02.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-20-02
Published: 02 May 2024
View article titled, Abstract PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)
Journal Articles

Abstract PO2-03-06: Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)

Filipa Lynce, Samuel Niman, Anthony Gonçalves, Megumi Kai, Sean Ryan, Elizabeth Troll, Rachel Layman, Antonio Giordano, Azadeh Nasrazadani, Faina Nakhlis, Jennifer Bellon, Laura Warren, Caroline Block, Susan Schumer, Anthony Lucci, Savitri Krishnamurthy, Florence Lerebours, Florence Dalenc, Christelle Levy, Thierry Petit, Marianne Leheurteur, Thomas Bachelot, Olivier Trédan, Sylvain Ladoire, Leonor Lopez Almeida, Christophe Zemmour, Sara Tolaney, Vicente Valero, François BERTUCCI, Meredith Regan, Wendy Woodward
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-03-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-03-06
Published: 02 May 2024
View article titled, Abstract PO2-03-06: Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)
Journal Articles

Abstract PO2-15-10: Identifying new immune-related biomarkers in TNBC with a look at PD-L1 cell-autonomous role

Caterina Costa, Claudia von Arx, Alessandra Calabrese, Francesca Pentimalli, Mutti Luciano, Antonio Giordano, Michelino De Laurentiis
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-15-10.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-15-10
Published: 02 May 2024
View article titled, Abstract PO2-15-10: Identifying new immune-related biomarkers in TNBC with a look at PD-L1 cell-autonomous role
Journal Articles

Abstract CT063: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

Sara A. Hurvitz, Fabrice André, Massimo Cristofanilli, Giuseppe Curigliano, Antonio Giordano, Hyo S. Han, Miguel Martín, Barbara Pistilli, Hope S. Rugo, Robert Wesolowski, Samuel Suzuki, Sarah C. Mutka, Igor Gorbatchevsky, Sibylle Loibl
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT063.
https://doi.org/10.1158/1538-7445.AM2023-CT063
Published: 14 April 2023
View article titled, Abstract CT063: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)
Journal Articles

Abstract OT3-26-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

Sara Hurvitz, Fabrice Andre, Massimo Cristofanilli, Giuseppe Curigliano, Antonio Giordano, Hyo S. Han, Miguel Martín, Barbara Pistilli, Hope Rugo, Robert Wesolowski, Samuel Suzuki, Sarah C. Mutka, Igor Gorbatchevsky, Sibylle Loibl
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT3-26-02.
https://doi.org/10.1158/1538-7445.SABCS22-OT3-26-02
Published: 01 March 2023
View article titled, Abstract OT3-26-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)
Journal Articles

Abstract OT1-03-01: XMT-1660: A Phase 1b trial of a B7-H4 targeted Antibody Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

Erika Hamilton, Arvind Chaudhry, Alexander I. Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo S. Han, Amy Weise, Aubri Marchesani, Kate Josephs, Chu Ri Shin, Kevin Kalinsky
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT1-03-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT1-03-01
Published: 01 March 2023
View article titled, Abstract OT1-03-01: XMT-1660: A Phase 1b trial of a B7-H4 targeted Antibody Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers
Journal Articles

Abstract 97: Mechanisms of action and regulation of the progranulin/EphA2 axis in mesothelioma

Elisa Ventura, Simone Buraschi, Stephen J. Williams, Antonino Belfiore, Renato V. Iozzo, Antonio Giordano, Andrea Morrione
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 97.
https://doi.org/10.1158/1538-7445.AM2022-97
Published: 15 June 2022
View article titled, Abstract 97: Mechanisms of action and regulation of the progranulin/EphA2 axis in mesothelioma
Journal Articles

Abstract 107: Data mining analysis of the PP2A-cell cycle axis in breast and prostate cancer patients

Ylenia Cendon-Florez, Raffaella Pippa, Silvia Boffo, Maria D. Odero, Antonio Giordano
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 107.
https://doi.org/10.1158/1538-7445.AM2020-107
Published: 15 August 2020
View article titled, Abstract 107: Data mining analysis of the PP2A-cell cycle axis in breast and prostate cancer patients
Journal Articles

Abstract A20: Pin1 as a regulator of multiple targets of cell growth in lung cancer

Silvia Boffo, Barbara D'Angelo, Andres J. Klein-Szanto, Marcella Macaluso, Antonio Giordano
Journal: Cancer Research
Cancer Res (2018) 78 (10_Supplement): A20.
https://doi.org/10.1158/1538-7445.MOUSEMODELS17-A20
Published: 14 May 2018
View article titled, Abstract A20: Pin1 as a regulator of multiple targets of cell growth in lung cancer
Journal Articles

Abstract 2232: Immune-inflammatory markers predict the outcome of metastatic colorectal cancer patients treated with the thymidylate synthase poly-epitope peptide (TSPP) vaccine: results from a multi-arm TSPP/VAC phase Ib program

Pierpaolo Correale, Cirino Botta, Elodia Claudia Martino, Valerio Nardone, Cristina Ulivieri, Claudia Gandolfo, Tatiana Cosima Baldari, Stefano Lazzi, Alessandro Ginori, Antonella Fioravanti, Giacomo Maria Guidelli, Luigi Pirtoli, Antonio Giordano, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Grazia Cusi
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2232.
https://doi.org/10.1158/1538-7445.AM2016-2232
Published: 15 July 2016
View article titled, Abstract 2232: Immune-inflammatory markers predict the outcome of metastatic colorectal cancer patients treated with the thymidylate synthase poly-epitope peptide (TSPP) vaccine: results from a multi-arm TSPP/VAC phase Ib program
Journal Articles

Abstract 3747: Oncolytic viruses as a possible therapeutic strategy against malignant mesothelioma

Carmelina Antonella Iannuzzi, Carmela Passaro, Silvia Boffo, Iris Maria Forte, Paola Indovina, Marcella Macaluso, Giuseppe Portella, Antonio Giordano, Francesca Pentimalli
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3747.
https://doi.org/10.1158/1538-7445.AM2016-3747
Published: 15 July 2016
View article titled, Abstract 3747: Oncolytic viruses as a possible therapeutic strategy against malignant mesothelioma
Journal Articles

Abstract 4190: A mouse model of pRb2/p130 in prostate cancer

Silvia Boffo, Andres J. Klein-Szanto, Flavio Rizzolio, Antonio Giordano
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4190.
https://doi.org/10.1158/1538-7445.AM2015-4190
Published: 01 August 2015
View article titled, Abstract 4190: A mouse model of pRb2/p130 in prostate cancer
Journal Articles

Abstract LB-080: Reactivating RBL2/p130 oncosuppressive function as a new, possible antitumoral strategy

Francesca Pentimalli, Luca Esposito, Iris Maria Forte, Carmelina Antonella Iannuzzi, Flavio Rizzolio, Tiziano Tuccinardi, Paola Indovina, Silvia Boffo, Antonio Giordano
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): LB-080.
https://doi.org/10.1158/1538-7445.AM2015-LB-080
Published: 01 August 2015
View article titled, Abstract LB-080: Reactivating RBL2/p130 oncosuppressive function as a new, possible antitumoral strategy
Journal Articles

Abstract 5295: Latent class longitudinal modeling of CTCs in ER+ metastatic breast cancer patients

Terry Hyslop, Xuechan Li, Rui Duan, Mario Giuliano, Antonio Giordano, Marlana Orloff, Hallgeir Rui, James M. Reuben, Massimo Cristofanilli
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5295.
https://doi.org/10.1158/1538-7445.AM2015-5295
Published: 01 August 2015
View article titled, Abstract 5295: Latent class longitudinal modeling of CTCs in ER+ metastatic breast cancer patients
Journal Articles

Abstract P6-14-07: High miR-19a serum levels correlate with favorable prognosis in patients with metastatic HER2+ inflammatory breast cancer and may result from an effective antibody-dependent cell-mediated cytotoxicity induced by trastuzumab

Simone Anfossi, Antonio Giordano, Lei Huo, Ricardo H Alvarez, Vicente Valero, Gabriel N Hortobagyi, Wendy A Woodward, Naoto T Ueno, George A Calin, James M Reuben
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P6-14-07.
https://doi.org/10.1158/1538-7445.SABCS14-P6-14-07
Published: 01 May 2015
View article titled, Abstract P6-14-07: High miR-19a serum levels correlate with favorable prognosis in patients with metastatic HER2<sup>+</sup> inflammatory breast cancer and may result from an effective antibody-dependent cell-mediated cytotoxicity induced by trastuzumab
Journal Articles

Abstract P2-06-05: Expression of the pluripotency transcription factor SOX2 in primary breast cancers (BCs): Correlation with clinicopathological features (CPfs) and recurrence

Barbara Pistilli, Giovanni Benedetti, Mauro Finicelli, Tiziana Squillaro, Andrea Marcellusi, Tommasina Biscotti, Alfredo Santinelli, Paola Mariani, Paolo Decembrini, Giancarlo Ciccioli, Luciano Latini, Antonio Giordano, Umberto Galderisi
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P2-06-05.
https://doi.org/10.1158/1538-7445.SABCS14-P2-06-05
Published: 01 May 2015
View article titled, Abstract P2-06-05: Expression of the pluripotency transcription factor SOX2 in primary breast cancers (BCs): Correlation with clinicopathological features (CPfs) and recurrence
Journal Articles

Abstract P4-01-04: Circulating tumor cells (CTC) are associated with defects in innate and adaptive immunity in inflammatory breast cancer (IBC) patients

Michal Mego, Hui Gao, Evan N Cohen, Simone Anfossi, Antonio Giordano, Sanda Tin, Tamer M Fouad, Wendy A Woodward, Ricardo H Alvarez, Vicente Valero, Naoto T Ueno, Gabriel N Hortobagyi, Massimo Cristofanilli, James M Reuben
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P4-01-04.
https://doi.org/10.1158/1538-7445.SABCS14-P4-01-04
Published: 01 May 2015
View article titled, Abstract P4-01-04: Circulating tumor cells (CTC) are associated with defects in innate and adaptive immunity in inflammatory breast cancer (IBC) patients